Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

Launched by HEPQUANT, LLC · Jul 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new blood test called the HepQuant DuO to see how well the liver recovers in people who have recently had liver damage caused by alcohol. The test involves drinking a natural substance called cholate and then taking two blood samples within an hour. By measuring how the liver processes this substance, doctors hope to better understand liver function and improve care for patients with alcohol-related liver disease.

Adults who have liver problems due to alcohol use, including those with a combination of alcohol-related liver disease and a condition called nonalcoholic steatohepatitis (NASH), may be eligible to join. Participants will visit the clinic four times over a year—at 1, 3, 6, and 12 months—where they will have the HepQuant DuO test and other routine blood tests. They will also be asked about their alcohol use, symptoms, and overall quality of life. This study is currently recruiting people aged 18 and older, and it aims to help doctors better monitor and treat liver disease caused by alcohol.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult with a clinical diagnosis of liver disease due to alcohol who have acute hepatic decompensation.
• • adult with a combined clinical diagnosis of alcohol-related liver disease (ALD) and nonalcoholic steatohepatitis (NASH).
• Exclusion Criteria:
• • Clinical diagnosis of liver disease with an etiology other than alcohol liver disease unless it is a combined clinical diagnosis of ALD and NASH.
• • patients with solid organ malignancy.
• • patients with other disease affecting the liver including autoimmune, drug-related liver injury, hemochromatosis or Wilson's disease
• • pregnancy
• • under the age of 18